ATP2A1 inhibitors(Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 inhibitors), SERCA2 inhibitors(Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 inhibitors)

Therapeutic Areas

Infectious DiseasesNeoplasmsImmune System Diseases+ [7]

Active Indication

MalariaHIV InfectionsUterine Cervical Cancer+ [9]

Inactive Indication

Anal intraepithelial neoplasiaAnal Precancerous ConditionCrohn Disease+ [4]

Originator Organization

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Active Organization

Frantz Viral Therapeutics LLCLineberger Comprehensive Cancer Center

Shanghai Jiao Tong University

+ [9]

Inactive Organization

Sanjay Gandhi Post Graduate Institute of Medical Sciences

Pfizer Inc.

License Organization-

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1988),

Malaria

RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Australia), Priority Review (Australia), Orphan Drug (United Kingdom)

Structure/Sequence

Molecular FormulaC19H28O8

InChIKeyFIHJKUPKCHIPAT-AHIGJZGOSA-N

CAS Registry88495-63-0

202

Clinical Trials associated with Artesunate

NCT06872112

/ Not yet recruitingPhase 1IIT

Phase I Study: A Dose-Escalation Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension

This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.

Start Date01 Jan 2026

Sponsor / Collaborator

Stanford University

NCT07095309

/ Not yet recruitingPhase 2

Phase II Randomised, Double Blind, Placebo Controlled Trial of Neoadjuvant Artesunate in Stage II/III Colorectal Cancer

TThis study evaluates the safety and effectiveness of pre-operative artesunate, given orally once a day for 14 days prior to surgery, in patients with Stage II/III colorectal cancer.
Artesunate is an established antimalarial drug with an excellent safety profile. It is well tolerated, affordable, and widely available. Several laboratory studies and one small pilot clinical study in patients with colorectal cancer have shown that artesunate can reduce the proliferation and growth of cancer cells.
One hundred patients diagnosed with Stage II/III operable colorectal cancer will be randomly allocated to receive oral artesunate 200 mg daily or a matching placebo for 14 days prior to surgery. Patients will then be followed closely for 5 years to determine whether pre-operative artesunate reduces the risk of cancer recurrence after surgery.

Start Date15 Aug 2025

Sponsor / Collaborator

Metanoic Health Ltd.

NCT07095478

/ Not yet recruitingPhase 2

Phase II Single Arm, Open Label Study of Artesunate for the Treatment of Human Papilloma Virus Positive High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

NeoART-CIN is a Phase II clinical study evaluating the safety and effectiveness of oral artesunate in patients with pre-cancerous cervical intra-epithelial neoplasia (CIN2/3), to investigate if a course of treatment with oral artesunate can reverse pre-cancerous changes in the cervix and prevent the development and progression of invasive cancer. Findings from this study will increase our understanding of the effects of artesunate on CIN2/3 and if confirmatory inform future clinical studies.

Start Date01 Aug 2025

Sponsor / Collaborator

Metanoic Health Ltd.

100 Clinical Results associated with Artesunate

100 Translational Medicine associated with Artesunate

100 Patents (Medical) associated with Artesunate

4,526

Literatures (Medical) associated with Artesunate

01 Jan 2026·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Biomimetic platelet membrane-engineered nanoplatforms for self-reinforcing ferroptosis-PDT synergy in oral tongue squamous cell carcinoma

Article

Author: Shu, Cheng-Jun ; Weng, Shu-Ping ; Zhu, Chun-Qi ; Lu, Han-Ze

Oral tongue squamous cell carcinoma (OTSCC), characterized by aggressive progression and limited therapeutic efficacy, urgently demands innovative strategies to circumvent surgical morbidity and hypoxia-driven resistance. To address this, we developed platelet membrane -cloaked P@Ce6-AS nanoparticles, co-assembling artesunate (AS, ferroptosis inducer) and chlorin e6 (Ce6, photosensitizer) for synergistic ferroptosis-photodynamic therapy (PDT). Platelet membrane coating endowed P@Ce6-AS with CD47-mediated immune evasion and P-selectin/CD44-targeted delivery, achieving uniform morphology, pH-responsive drug release, and lysosome-triggered payload liberation. In vitro, P@Ce6-AS exhibited 4.95-fold higher tumor cell uptake than free Ce6 and Ce6-AS, with deep spheroid penetration. P@Ce6-AS exerted potent antitumor activity by orchestrating a multifaceted cytotoxic response, synergistically inducing GPX4-mediated ferroptotic lipid peroxidation and mitochondrial apoptosis to profoundly suppress CAL-33 cell viability. Collectively, this biomimetic nanoplatform demonstrates significant potential for clinical translation by overcoming hypoxia-driven therapeutic resistance while minimizing off-target toxicity, offering a paradigm shift in precision OTSCC management.

31 Dec 2025·Future Science OA

Spectrophotometric analysis of artesunate injections available in community pharmacies in Northern and Western Uganda

Article

Author: Ayogu, Ebere Emilia ; Ezeonwumelu, Joseph Obiezu Chukwujekwu ; Sadiq, Bashir Olaniyi ; Wawata, Ibrahim Garba ; Ngolryeko, Emmanuel Aryon

AIM:

The surge in different brands of artesunate injection in Uganda, has raised the need for this study, which aimed at quantifying the actual amount of artesunate in different brands of artesunate injections available in Northern and Western Uganda.

MATERIALS AND METHODS:

The wavelength at maximum absorbance of pure artesunate powder was determined using Ultraviolet-visible spectrophotometer and Beer Lambert's plot was generated. This was validated and used to assay 27 brands of artesunate.

RESULTS:

In the spectrophotometric assay method used, Beer Lambert's law was obeyed within the range of 20 µg/ml-140 µg/ml with linear regression equation of y = 0.012 + 0.030 and correlation coefficient of (R²) 0.999 (n = 9). The limits of detection (sensitivity) and quantification were found to be 0.83 mg/ml and 2.09 mg/ml respectively. About 66.6% (18) and 33.3% (9) had actual artesunate content higher and lower than labeled claim respectively, while 40.7% (11) had deviations from labeled claim that were within acceptable limits.

CONCLUSION:

Most brands of artesunate injection assayed deviated from labeled claim, regional/environmental factor impacted much on the stability of artesunate thus there is need for further screening of the quality of artesunate injection in circulation in view of the therapeutic consequences of substandard artesunate injection.

31 Dec 2025·SCIENCE AND TECHNOLOGY OF ADVANCED MATERIALS

Poly(ARTEMA), a novel artesunate-based polymer induces ferroptosis in breast cancer cells

Article

Author: Ito, Natsumi ; Ebara, Mitsuhiro ; Nabil, Ahmed ; Uto, Koichiro

Ferroptosis, a form of non-apoptotic cell death, is emerging as a promising strategy for cancer therapy. Artesunate (ART), an extract obtained from the traditional Chinese medicine Qinghaosu, has been shown to exhibit anti-cancer activity by inducing ferroptosis in cancer cells. While previous research has focused on incorporating ART monomer into drug delivery systems for enhanced cancer targeting, this study presents 2-methacryloyloxyethyl ART polymer (poly(ARTEMA)), a novel polymer synthesized from ART for the first time. Our goal was evaluation of poly(ARTEMA) anticancer potential on breast cancer cells. First, we synthesized ARTEMA using esterification followed by its polymerization using the reversible addition-fragmentation chain transfer (RAFT) polymerization method. We evaluated its mechanism of action, focusing on two key pathways: temperature-triggered singlet oxygen generation and ferrous ions (Fe²⁺) release, both of which contribute to ferroptosis. Our results demonstrate that poly(ARTEMA) selectively generates singlet oxygen and Fe²⁺ due to the endoperoxide crosslinks, leading to cell death in breast cancer cells. We also investigated the anti-cancer potential of poly(ARTEMA) on breast cancer cells with and without a ferroptosis inhibitor. The IC₅₀ values were 125 µM for the MCF-7 cancer cell line and 300 µM for the normal MCF-10 cell line, indicating enhanced toxicity toward cancer cell lines. These findings suggested that poly(ARTEMA) induces ferroptosis in cancer cells and may serve as a promising candidate for cancer therapy with minimal cytotoxicity. To the best of our knowledge, this report may be the first that successfully synthesized poly(ARTEMA) using ART, with its anticancer potential evaluation.

News (Medical) associated with Artesunate

31 Mar 2025

·www.prnewswire.com

Guo Guangchang's Letter to Shareholders: Fosun International Pursues Progress through "Strategic Advancements and Exits"

HONG KONG, March 31, 2025 /PRNewswire/ -- Guo Guangchang, Chairman of Fosun International Limited (HKEX: 0656), issued a letter to its shareholders on 30 March, outlining the Company's strategic direction, accomplishments, and future plans. Dear shareholders, The year 2024 concluded successfully, thanks to the collective efforts of all Fosuners. Looking back on the past year, we sustained steady growth momentum and demonstrated robust resilience in the face of global economic fluctuations and market challenges. We continuously advanced our core business-focused and business streamlining strategy by divesting non-core assets and heavy assets to focus on core operations, reduce debt, and optimize our capital structure. The signed asset divestment amounted to approximately RMB17.5 billion equivalent at the group level, and approximately RMB30.0 billion equivalent at the consolidated level. In the course of asset divestment, the adjustment in the carrying value of an individual investment impacted our 2024 financial performance. Nonetheless, Fosun's overall operational fundamentals remain stable, the core businesses are under healthy development, and the industrial operation profits and operating cash flows stay healthy and stable. Looking ahead, we will further deepen our focus on core industries, leveraging our globalization and innovation capabilities to create long-term and stable value for our shareholders. Focusing on core businesses, achieving success through "strategic advancement s and exits" Over the past few years, we have remained committed to our core business-focused and business streamlining strategy. While some companies and teams have bid farewell to the Fosun family during this period, I can assure you that we have never sold any company at a low price merely to offload assets. Their departure was not a result of hasty sale, but rather a deliberate decision made in line with our long-term strategy to sharpen focus on future development. Throughout this collaborative journey, we have consistently fostered win-win outcomes with our partners. The value achieved by these companies underscores our unwavering commitment and effective management over the years, continually driving enhancements to their intrinsic value. I am deeply grateful to the management teams who have led these outstanding companies forward, as their exceptional performance has enabled Fosun to navigate challenging environments with stability. In 2022 and 2023, we dedicated ourselves to a business streamlining strategy that reinforced our foundation and enabled us to advance with greater agility. In 2024, we placed greater emphasis on "balanced investment and divestment, strategic advancements and exits". While remaining committed to the divestment of non-core businesses, we also prioritized the "advancement" of our core operations, thereby ensuring sustainable growth for the Company and creating greater value for our shareholders. As a result, throughout the past year, we made notable "advancements" by focusing on our core industries. In health business, Fosun Pharma increased its stake in Fosun Kairos to 100%, which specializes in the research and development (" R&D"), manufacturing and commercialization of CAR-T cell therapy. In tourism and culture business, the ULTRAMED Hainan project in Sanya was officially launched, introducing world-class water entertainment facilities to create an AI-themed resort that integrates diverse experiences. Additionally, our proposal for the privatization of FTG was approved by a majority vote of FTG shareholders, allowing FTG to accelerate development with greater flexibility. With years of accumulation and thoughtful cultivation, we have ushered in key development opportunities for the two domestic insurance companies. The total premium income of Pramerica Fosun Life Insurance surged from RMB4,346 million in 2023 to RMB9,251 million at 2024, while Fosun United Health Insurance also experienced steady growth in premium income, and both companies achieved profitability. The continuous growth of these two companies has laid a strong foundation for Fosun's future development. After more than 30 years of steady development, Fosun has developed strong competitive advantages across multiple sectors and has gained a profound understanding of its core capabilities. Accordingly, we will concentrate on these competitive and advantageous industries, pursuing our vision of "helping global families live in health, happiness, and wealth until the age of 121". We will focus on "deep mining", which involves prioritizing the development of our core industries, including health, tourism and culture, consumption, and insurance, thereby achieving stable profit growth in the long run. Combining global growth momentum with global resources Fosun is both a practitioner and beneficiary of globalization. In 2024, our overseas revenue proportion further increased to 49.3%, and the number of overseas employees accounted for nearly half of the Group's total number of employees. In the past, we proposed combining China's growth momentum with global resources. Now, I believe we should integrate global growth momentum with global resources, along with China's competitiveness. We should fully mobilize our unique advantages in efficiency, innovation, resources, and costs, and combine them with global networks and capabilities. In terms of global expansion, all our segments achieved new breakthroughs. In health business, Fosun Pharma has evolved from adopting a "product export model" to establishing global operational capabilities that encompass the "comprehensive internationalization of research, manufacturing, and sales". Henlius has made significant strides in global market expansion. Taking the independently developed monoclonal antibody HANQUYOU as an example, it was approved for marketing in more than 50 countries and regions, and in 2024, it further expanded its commercial supply to the North American market. In insurance business, Fosun Insurance Portugal fully leveraged Fosun's "global organization + local operations" capabilities, with gross written premiums reaching approximately EUR6,172 million in 2024. Through overseas expansion, the proportion of Fosun Insurance Portugal's international business increased from less than 5% in 2014 to 29.8%. In cultural business, the Yuyuan Garden Lantern Festival celebrated its 30th anniversary and once again gained widespread popularity during the Year of the Snake edition, significantly driving overall consumption in the Yuyuan Garden commercial district during the Spring Festival. Following its successful overseas debut in Paris, France in 2023, the Yuyuan Garden Lantern Festival has embarked on another overseas journey in 2025. In January 2025, the Yuyuan Garden Lantern Festival themed lantern installation made a stunning appearance in Hanoi, Vietnam, commemorating the 75th anniversary of the establishment of diplomatic relations between China and Vietnam. This year, it will also be featured in Thailand, continuing to showcase the charm of oriental culture globally. In resources and energy business, Hainan Mining continued its international expansion, focusing on strategic resources. It successively acquired oil interests in Oman and proposed to acquire zirconium-titanium mine projects in Mozambique, thereby expanding its oil and gas business, enriching its strategic metal reserves, and broadening its profit channels. Driving long-term development with innovation We fully recognize that in today's fiercely competitive market, mere extensive and repetitive development is no longer adequate to overcome challenges and may easily result in the pitfalls of involution. We must enhance our competitiveness by developing core technologies through innovation to drive long-term development. Accordingly, Fosun firmly positions technology innovation as its strategic core. In 2024, the Group's total investment in technology innovation[1] reached approximately RMB6.9 billion. We have established more than 20 global technology innovation centers covering various industries and fields, continuously fostering the launch of new technologies and products. As time passes, our innovative achievements have evolved and undergone qualitative transformations. As one of the first Hong Kong-listed "18A" pharmaceutical companies which turned to profit through product sales, Henlius built on its initial profit in 2023 and maintained strong growth in 2024. It successfully achieved sustained profitability with a net profit of RMB820 million, representing a year-on-year increase of 50.3%. In early 2025, its core product, HANSIZHUANG (European trade name: Hetronifly®), an anti-PD-1 monoclonal antibody, was approved for marketing in the European Union. This milestone makes it the first and only PD-1 innovative drug approved for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in the European Union. In addition, Intuitive Fosun's Ion Robotic Bronchoscopy (" Ion System") was launched in China, enabling more lung cancer patients to achieve early diagnosis and treatment in a minimally invasive manner. Furthermore, the high-end tourist train "Silk Road Express" officially commenced operations, making it the first international luxury sightseeing train in China and filling the gap in the domestic market. Last year, I shared our perspectives on the artificial intelligence (AI) era, and we were envisioning its potential. This year, the application of AI has rapidly infiltrated various aspects of our lives, developing at a pace that far exceeds our expectation. Fosun's approach to AI is not to develop a large model by ourselves, but rather to deeply integrate AI technology into our diverse scenarios to drive innovation and enhance efficiency. For instance, Fosun Pharma launched the PharmAID decision intelligence platform, which integrates information extraction, patent insights, business forecasting, and more. With data updated at T+1, it supports accurate and efficient decision-making to accelerate and improve the drug R&D. Sisram is also exploring the use of AI for precise skin analysis and personalized skin care solutions. The ULTRAMED Hainan project is set to create the world's first AI-themed resort by utilizing AIGC technology for guest room customization. It will also introduce the digital human G.O (Gentle Organizer) service to enhance tourist experience. Regarding corporate operations and management, I encourage Fosuners to consider how to fully integrate AI into daily work comprehensively for more precise decision support and strategic assessments. Harnessing the flywheels of "insurance + industry + investment", leveraging operational capabilities to implement the asset-light strategy To achieve more effective resource allocation and drive sustainable value growth, we have integrated Fosun's profound industry expertise, extensive investment experience, and high-quality commercial resources with the operations and investments of insurance companies, forming a three-dimensional "insurance + industry + investment" flywheel-driven strategy. The collaborative growth of domestic and international insurance companies and Fosun's various industries has laid a strong foundation for the "insurance + industry + investment" flywheel-driven strategy that we have always advocated. At the same time, Fosun's unique ecosystem synergy model further amplifies the flywheel effect. In 2024, we successfully implemented the "health care + insurance" ecosystem policy model, with 14,000 community health care policies sold, totaling premiums of RMB12.85 billion. Fosun Care achieved profitability for the first time, laying a solid foundation for flywheel development. As part of our strategic direction, we made significant progress in asset-light operations in 2024. Fosun Pharma together with the Shenzhen Guidance Fund and other investors established a RMB5.0 billion biopharmaceutical industry fund to jointly promote the high-quality development of the pharmaceutical and healthcare industry in the Greater Bay Area. In addition, FTG's Taicang Alps Resort Phase II project, Jinsha Bay project in Dapeng New District, Shenzhen, and other projects were signed and commenced in 2024. Objectively, given the current market environment, heavy asset investments using our core capital do not yield returns that align with capital costs. However, low-cost funds, including those from insurance, inherently require heavy asset allocations. Therefore, to bolster our asset-light operations, it is essential to strengthen cooperation with insurance institutions and others, empowering our investment and operational capabilities. Healthy financial position, "Contribution to Society" through ESG initiatives We adhere to a prudent financial management strategy, continuously optimizing our capital structure and financing channels to gain the trust of capital markets. During 2024, Fosun repaid a total of RMB11.1 billion equivalent matured public bonds in onshore and offshore markets. We sincerely thank both domestic and international investors, as well as financial institutions, for their continuous recognition over the years. During 2024, we successfully issued USD300 million offshore bonds and obtained a sustainability-linked syndicated loan. Looking ahead, we will continue to capitalize on favorable interest rates through meticulous management and prudent leverage control. We will remain focused on divesting non-core and non-strategic assets, reducing the Group's interest-bearing debts, and strengthening our resilience to economic cycles, striving to attain "investment grade" ratings at the earliest opportunity. Fosun remains steadfast in its commitment to "Self-improvement, Teamwork, Performance, and Contribution to Society" and "Developing Business for Good". In 2024, we officially launched the "Create IMPACT" sustainable development strategy to closely integrate commercial value with social value. The "Rural Doctors Program" initiated by Fosun Foundation was recognized as an excellent case for sustainable development practice by the United Nations, serving as a model for enhancing primary healthcare and showcasing the international impact of Fosun's philanthropic efforts. Fosun Pharma has supplied a cumulative total of over 400 million doses of Artesun® (artesunate for injection) to the global market, saving more than 80 million severe malaria patients worldwide. Our sustainable development practices have also received recognition from international authorities, with an MSCI ESG rating maintained at AA for four consecutive years. In the future, we will continue to advance the "Create IMPACT" strategy and actively contribute to global sustainable development. Looking ahead to 2025, despite still facing certain pressures, we have begun to see signs of recovery in the broader market, and our results have reflected this trend. During the Spring Festival, Atlantis Sanya achieved an outstanding occupancy rate of over 98%; Tuopai T68 baijiu recorded an 80% year-on-year increase in sales revenue, thanks to its superior price-to-quality proposition; our Club Med winter resorts in China and Hokkaido, Japan continued to experience strong demand throughout the peak season. These achievements reinforce our great confidence in future development. We extend our heartfelt gratitude to our shareholders for your unwavering understanding and support over the past year. We are well-prepared to tackle challenges and pursue progress through "strategic advancements and exits", while continuing to deepen our development in core industries. We are confident in our ability to maintain steady development, create long-term value for our shareholders, and contribute to healthier, happier, and wealthier lives for families worldwide. Guo Guangchang 30 March 2025 SOURCE Fosun WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalPhase 2

30 Mar 2025

·www.prnewswire.com

Fosun International Announces 2024 Annual Results: Total Revenue Reaches RMB192.14 Billion, Industrial Operation Profit Amounts to RMB4.9 Billion, Overall Operational Fundamentals Remain Stable

2024 Annual Results Highlights: Total revenue reached RMB192.14 billion; Industrial operation profit amounted to RMB4.9 billion; Total revenue generated by the four core subsidiaries amounted to RMB134.65 billion, accounting for 70.1% of the Group's total revenue; Total debt to total capital ratio was 52%; cash, bank balance and term deposits amounted to RMB106.34 billion; The proportion of overseas revenue rose to 49.3%, representing a year-on-year increase of 6.2%; Investment in technology innovation reached approximately RMB6.9 billion. HONG KONG, March 30, 2025 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group"), today announced its annual results for the year ended 31 December 2024 (the "Reporting Period"). In 2024, Fosun pressed ahead with its strategy of "business streamlining and advancements and exits", while deepening its focus on the household consumption sector in the face of global economic fluctuations and market challenges. By leveraging globalization, innovation, and asset-light operations, the Group advanced the development of its core industries, resulting in stable overall operational fundamentals. During the Reporting Period, the Group's total revenue reached RMB192.14 billion. Its four core subsidiaries – Yuyuan, Fosun Pharma, Fosun Insurance Portugal, and Fosun Tourism Group ("FTG") – generated a total revenue of RMB134.65 billion, accounting for 70.1% of the Group's total revenue, supported by a solid asset base. During the Reporting Period, the Group's industrial operation profit reached RMB4.9 billion, demonstrating stable operational fundamentals. The Group's loss attributable to owners of the parent amounted to RMB4.35 billion, mainly due to a one-off non-cash loss during the Reporting Period. Excluding this significant one-off effect, the profit attributable to owners of the parent amounted to RMB0.75 billion. In 2024, Fosun's operating cash flow remained healthy and stable. The Group consistently optimized its asset portfolio. The signed asset divestment amounted to approximately RMB17.5 billion equivalent at the group level, and approximately RMB30.0 billion equivalent at the consolidated level, thereby further optimizing the balance sheet and building up liquidity buffer. As at the end of the Reporting Period, the Group's total debt to total capital ratio was 52.0%, cash and bank balance and term deposits amounted to RMB106.34 billion. Healthy debt ratios and abundant funds can strengthen the Group's resilience against external risks while enhancing its ability to capture investment opportunities. In November 2024, after an absence of three years, Fosun returned to the offshore USD bond market and successfully issued long duration USD bonds, substantially expanding its offshore financing options. In terms of bank financing, Fosun refinanced its three-year unsecured syndicated loan with upsize from matured loan, achieving the successful launch of offshore syndicated loans for 8 consecutive years. Fosun High Technology issued several super short-term commercial papers, raising a total of RMB5.1 billion. In June 2024, the international credit rating agency S&P fully recognized the Group's steady improvement in credit matrix, and reaffirmed the BB- rating and a stable credit outlook. Guo Guangchang, Chairman of Fosun International, stated, "We believe that the clear strategic focus and robust industrial operational capabilities are the key to driving Fosun's long-term steady development. Looking ahead, we will further deepen our focus on core industries. By leveraging our globalization and innovation capabilities, we believe that we can create long-term, stable value for our shareholders, even in a challenging environment." Demonstrating ongoing success in globalization efforts As a global innovation-driven consumer group rooted in China, Fosun has continued to deepen its industrial presence in over 35 countries and regions, consolidating its global operational capabilities. In 2024, the Group's overseas revenue grew 6.2% year-on-year, increasing the proportion of overseas revenue to 49.3% of total revenue. High-quality global operations have become a new growth engine for Fosun. Benefiting from the forward-looking internationalization strategy, Henlius achieved overseas product sales revenue of RMB121 million in 2024, representing a substantial increase of 30.76% over the same period last year. HANSIZHUANG was approved for marketing in the European Union; HANQUYOU was approved for marketing in the U.S. and Canada, embarking on a new journey of commercialization in North America; HANLIKANG, the first biosimilar approved in China, was approved for marketing in Peru, Nicaragua and Bolivia; HANBEITAI was approved for marketing in Bolivia. Henlius now has four self-developed and self-manufactured products approved for overseas marketing, demonstrating ongoing success in its globalization efforts. In 2024, Fosun Insurance Portugal maintained its high-quality and sustainable growth, achieving growth in both domestic and international businesses with total gross written premiums reaching approximately EUR6,172 million. Both the combined ratio and revenue from the insurance business outperformed those of the same period in 2023. In addition, Fosun Insurance Portugal's overseas revenue reached EUR1.84 billion, fully demonstrating Fosun's capabilities of "global organization + local operations". Through overseas expansion, the proportion of international business increased from less than 5% in 2014 to 29.8%. In May 2024, Fosun entered into an agreement with ABN AMRO Bank N.V. to sell all of its equity interest in HAL, a leading private bank in Germany. Meanwhile, the Group will retain all the shares of Hauck & Aufhäuser Fund Services S.A. ("HAFS") indirectly held by HAL. HAFS plans to further expand its fund administration functions and create synergies with Fosun's operations in the financial and insurance sector in Europe. Since the initial investment in HAL in 2016, through continuous strengthening of industrial operations and ecosystem synergies, Fosun achieved an internal rate of return of nearly 14% on this investment up to the disposal. In the resources and energy business, Hainan Mining has continued its international expansion, expanding its oil and gas business, enriching its strategic metal reserves, and enhancing profitability. During the Reporting Period, Hannan Mining completed the acquisition of oil interests in four oil blocks in Oman and initiated the acquisition of two producing zirconium-titanium mines in Mozambique. As of March 2025, Phase I of the Bougouni lithium mine in Mali, Africa has achieved the conditions for continuous and stable production. In the cultural business, following the successful overseas debut in Paris, France in 2023, the Yuyuan Garden Lantern Festival has embarked on another overseas journey in 2025. In January 2025, the Yuyuan Garden Lantern Festival themed lantern installation made a stunning appearance in Hanoi, Vietnam, commemorating the 75th anniversary of the establishment of diplomatic relations between China and Vietnam. This year, it will also be featured in Thailand, continuing to showcase the charm of oriental culture globally. Leveraging technology innovation to enhance product strength Fosun regards technology innovation as a core strategic pillar and has established a global innovation system integrating "independent research and development ('R&D') + investment incubation + ecosystem collaboration". During the Reporting Period, the Group's investment in technology innovation amounted to approximately RMB6.9 billion. It has established more than 20 global technology innovation centers, covering various industries and fields, continuously fostering the launch of new technologies and products. In terms of R&D of innovative drugs, a total of 16 indications of 7 innovative drugs/ biosimilars independently developed or licensed-in by Fosun Pharma were approved for launch, including: Rabies vaccine (Vero cell) for human use (freeze dried) was approved for launch in Chinese mainland; and Trastuzumab for injection was approved for launch in the United States and Canada. As one of the first Hong Kong-listed "18A" pharmaceutical companies which turned to profit through product sales, Henlius successfully achieved sustained profitability in 2024 with a net profit of RMB820 million, representing a year-on-year increase of 50.3%. In terms of medical devices and medical diagnosis, the Ion Robotic Bronchoscopy ("Ion System") of Intuitive Fosun was approved by the National Medical Products Administration of the PRC; F-i6000 Automated Chemiluminescence Immunoassay Analyzer, F-C2000 Fully Automated High-Speed Chemiluminescence Analyzer, and Cytokine Detection Reagent (Chemiluminescence Method), which were independently developed by Fosun Pharma, were all approved for launch in Chinese mainland. Yuyuan has leveraged technology to empower traditional culture. This year's Yuyuan Garden Lantern Festival themed "Adventure of Mountain and Seas: The Jungle Chapter" leveraged VR technology to create the first immersive light and shadow exhibition featuring diverse landscapes inspired by "The Classic of Mountains and Seas" in China. It integrated AR live streaming, allowing tens of millions of viewers to participate in the exhibition online. Building on 30 years of experience, it showcased the transformation and upgrading of the traditional Spring Festival lantern festival into a modern urban cultural IP. Fosun Insurance Portugal has continued to build on its digital capabilities to drive the rapid growth of the insurance business. During the Reporting Period, the total number of digital users of Fosun Insurance Portugal exceeded 1.9 million, accounting for nearly 20% of Portugal's total population. Fosun is committed to deeply integrating AI technology into its diverse scenarios to drive innovation and enhance efficiency. For instance, Fosun Pharma launched the PharmAID decision intelligence platform, which integrates information extraction, patent insights, business forecasting, and more. With data updated at T+1, it supports accurate and efficient decision-making to accelerate and improve drug R&D. In addition, Sisram Medical is exploring the use of AI for precise skin analysis and personalized skin care solutions, etc. Focusing on core businesses with strategic advancements and exits, continuously amplifying the "flywheel effect" Fosun has continuously advanced its "business streamlining, and advancements and exits" strategy. While divesting some non-core assets, it has also focused on the development of core businesses to achieve "balanced investment and divestment". In 2024, Fosun Pharma increased its stake in Fosun Kairos to 100% to continuously focus on the R&D, manufacturing and commercialization of CAR-T cell therapy. In October 2024, the ULTRAMED Hainan project in Sanya was officially launched. It is set to create the world's first AI-themed resort by utilizing AIGC technology for guest room customization and introducing the digital human G.O (Gentle Organizer) service to enhance tourist experience. In addition, the Taicang Alps Resort Phase II project has been launched. It is developed by Taicang municipal government platform and managed by FTG. FTG also signed an asset-light operation agreement for the Jinsha Bay project in Shenzhen, marking the launch of the first Club Med in the Greater Bay Area. To achieve more effective resource allocation and drive sustainable value growth, Fosun has integrated its profound industry expertise, extensive investment experience, and high-quality commercial resources with the operations and investments of insurance companies, forming a three-dimensional "insurance + industry + investment" flywheel-driven strategy. Fosun's unique ecosystem synergy model has further amplified the flywheel effect. In 2024, it successfully implemented the "health care + insurance" ecosystem policy model, with 14,000 community health care policies sold, totaling premiums of RMB12.85 billion. Fosun Care achieved profitability for the first time, laying a solid foundation for flywheel development. As part of its strategic direction, Fosun made significant progress in asset-light operations in 2024. Fosun Pharma, together with the Shenzhen Guidance Fund and other investors, established a RMB5.0 billion biopharmaceutical industry fund to jointly promote the high-quality development of the pharmaceutical and healthcare industry in the Greater Bay Area, marking a significant milestone in the implementation of Fosun's asset-light strategy. Focusing on "Developing Business for Good" In 2024, Fosun centered on its corporate values of "Self-improvement, Teamwork, Performance, and Contribution to Society" to promote the deep integration of the ESG strategy and commercial value. It continuously contributed to global sustainable development through responsible investment, low-carbon transformation, and social initiatives. In addition, Fosun launched the "Create IMPACT" sustainable development strategy in 2024 to closely integrate commercial value with social value. Fosun's "Rural Doctors Program" was included in the "20 Cases of Private Sector's Sustainable Development in China for 20 Years" Report of the United Nations Global Compact. As at the end of 2024, the program had covered 78 counties in 16 provinces, municipalities and autonomous regions (including 21 key counties for national rural revitalization), assisted 15,000 administrative village clinics, supported 25,000 rural doctors, and benefited 16.34 million rural people in 3 million rural families. In terms of global public health cooperation, Fosun has actively participated in the "China-Africa Community Sustainability Action Network", contributing to the health development of African communities. Fosun Pharma has consistently contributed to the "China Solution", and announced that it would donate RMB10 million worth of artemisinin-based anti-malaria medicines to Africa in the next three years. As at the end of 2024, artesunate for injection independently developed by Fosun Pharma had been used to treat more than 80 million patients with severe malaria worldwide. Additionally, the company had supplied a cumulative total of over 400 million doses of artesunate for injection globally. During the Reporting Period, Fosun International maintained an MSCI ESG rating of AA, achieved an HSI ESG rating of AA-, ranked in the top 5% among global peers in S&P Global's Corporate Sustainability Assessment (CSA), and was selected as the top 1% in S&P Global's Sustainability Yearbook 2024 (China Edition) for its outstanding performance. Guo Guangchang, Chairman of Fosun International, said that Fosun is well-prepared to tackle challenges and pursue progress through "strategic advancements and exits", while continuing to deepen development in core industries. Looking ahead, the Group is confident in its ability to maintain steady development. SOURCE Fosun WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalPhase 2Acquisition

18 Dec 2024

·www.prnewswire.com

Fosun International Awarded TVB's Highest Honor "Outstanding ESG Award"

HONG KONG, Dec. 17, 2024 /PRNewswire/ -- On 13 December 2024, the "TVB ESG Awards" ceremony, hosted by Television Broadcasts Limited (hereinafter referred to as "TVB"), was held at the Hong Kong Convention and Exhibition Centre. Fosun International was honored with the highest accolade, the "Outstanding ESG Award", as well as awards for "Best in ESG Practices" and "Best in ESG Report". Officiating guests at the awards ceremony included Mr. Wong Wai Lun, Michael, GBS, JP, Deputy Financial Secretary of the Government of the Hong Kong Special Administrative Region (SAR), Mr. Chan Ho Lim, Joseph, JP, Under Secretary for Financial Services and the Treasury of the Government of the Hong Kong SAR, Mr. Wong Chuen Fai, JP, Commissioner for Climate Change, Environment and Ecology Bureau of the Government of the Hong Kong SAR, and Mr. Siu Sai Wo, General Manager (Business Operations) of TVB, who jointly presented the "Outstanding ESG Award" to Fosun International. TVB pointed out that Fosun International's recognition with the "Outstanding ESG Award", "Best in ESG Practices" and "Best in ESG Report" is well-deserved. After 30 years of development, Fosun has developed into a large globalized company with operations spanning healthcare, tourism, consumption, and insurance. With a robust global industrial ecosystem, Fosun operates responsibly in over 35 countries and regions, actively contributing to public welfare and creating sustainable value worldwide. Looking back on the past, Fosun has always paid attention to the reform and development of the global policies in the field of sustainable development. It has established a comprehensive ESG management system, integrated ESG management requirements into business management over the years, actively responded to national and global strategies in relation to sustainable development, ensured information security, promoted technology innovation, implemented "dual carbon" goals, protected the rights and interests of employees to promote sustainable management and value creation. This year, a total of five organizations received the prestigious "Outstanding ESG Award" from TVB, all of which have demonstrated excellence in ESG. These include government agency, major public utility, and well-known enterprises: the Drainage Services Department of the Government of the Hong Kong SAR, CLP Power Hong Kong Limited, Chinachem Group, and Crystal International Group. The companies awarded "Best in ESG Practices" and "Best in ESG Report" are all prominent firms in Hong Kong, including MTR Corporation, Henderson Land Development, Sino Land, and NWS Holdings. After accepting the "Outstanding ESG Award", Angel Sze, Company Secretary and Head of the ESG Management Committee of Fosun International, took part in a discussion with representatives from other award-winning organizations to share Fosun's ESG achievements. Actively giving back to society through innovation During the discussion, Angel Sze remarked, "Since its establishment, Fosun has remained dedicated to its original aspiration of 'Contribution to Society' and strives to create a positive impact through business. For instance, in our pharmaceutical business, we focus on technology innovation and have made significant breakthroughs in cancer treatment. The CAR-T cell therapy product Yi Kai Da (ejilunsai injection), developed by Fosun Kite, is the first CAR-T cell therapy approved for marketing in the Chinese mainland, bringing lymphoma patients more treatment options and hope for recovery." Thanks to the long-term accumulated technology innovation capabilities, Fosun has continued to realize the "world's first" and "China's first" achievements. Fosun Pharma's self-developed artesunate for injection saved more than 72 million patients with severe malaria around the world as of the first half of 2024. Its second-generation artesunate for injection (Argesun®) is the first injectable artesunate presented with a single solvent system to receive prequalification from the World Health Organization (WHO-PQ) for the treatment of malaria. Voluntarily releasing Climate Information Disclosures Report, calling for joint efforts towards carbon neutrality In 2021, Fosun made a commitment to society – "strive to peak carbon emissions by 2028 and achieve carbon neutrality by 2050". Fosun has formulated strategies for climate change mitigation and adaptation to align with the 1.5°C temperature control target set in the Paris Agreement. In order to achieve Fosun's carbon peaking and carbon neutrality goals, the Group has established a Carbon Neutrality Committee and a Carbon Neutrality Working Group to actively promote further implementation and enforcement of carbon-neutral management within the Group. In April this year, in the face of increasingly severe global climate change challenges, Fosun released its second Climate Information Disclosures Report with reference to the disclosure requirements of the Hong Kong Stock Exchange, the Task Force on Climate-Related Financial Disclosures (TCFD) recommendations and IFRS S2 Climate-related Disclosures, demonstrating its commitment of climate action to international community and calling on all sectors to jointly promote carbon neutrality. In terms of climate action, the Group and its member companies actively promote energy conservation and carbon reduction. Fidelidade, Fosun's insurance company in Portugal, has recently established the Impact Center For Climate Change (ICCC), a knowledge center dedicated to climate change research. Through collaborations with external entities, including universities, research centers, and public institutions, it provides scientific insights on the impacts of climate change on society, particularly in the insurance industry. In addition, The Group's Atlantis Sanya obtained the highest level of green building certification in China and other leading environmental certifications in the global tourism industry. The Bund Finance Center (BFC), Fosun's base in Shanghai and landmark in Shanghai, was awarded the LEED Platinum certification, which is hailed as the "Oscar Award" in the green building industry, with a score of 97 points to set a new world record. Fosun is committed to "globalization" and "innovation", striving to build a more responsible, inclusive and sustainable future This year, Fosun has formulated its sustainable development strategy: "Create IMPACT", which stands for I: Innovation-driven, M: Mindful Operation, P: People and Partner Oriented, A: Advanced Governance, C: Climate and Planet Positive and T: Transparency. This strategy continues Fosun's original aspiration of "Self-improvement, Teamwork, Performance and Contribution to Society", and serves as a foundation for long-term ESG practices. Rooted in China, Fosun has been developing globally and has long adhered to the two core growth drivers of "globalization" and "innovation". As one of the few Chinese companies with established global operational and investment capabilities, Fosun has cultivated profound expertise in technology and innovation. With an increasingly sophisticated global business presence, Fosun operates responsibly in more than 35 countries and regions, actively contributing to public welfare and creating sustainable value worldwide. Looking ahead, Fosun remains dedicated to advancing its social responsibility through innovation and responsible global operations. Guided by its "Create Impact" sustainable development strategy, Fosun will intensify its efforts to build a more responsible, inclusive and sustainable future. SOURCE Fosun WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalImmunotherapy

100 Deals associated with Artesunate

External Link

KEGG	Wiki	ATC	Drug Bank
D02482	Artesunate	P01BE03	DB09274

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Malaria	China	Guilin Pharmaceutical Co., Ltd.	01 Jan 1988

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 2	Kenya	Lineberger Comprehensive Cancer Center	22 Jan 2025
Uterine Cervical Cancer	Phase 2	Kenya	Lineberger Comprehensive Cancer Center	22 Jan 2025
Carcinoma in Situ	Phase 2	United States	Frantz Viral Therapeutics LLC	06 Dec 2023
Dysplasia	Phase 2	United States	Frantz Viral Therapeutics LLC	06 Dec 2023
Vulvar Diseases	Phase 2	United States	Frantz Viral Therapeutics LLC	06 Dec 2023
Anal intraepithelial neoplasia	Phase 2	United States	Frantz Viral Therapeutics LLC	10 Feb 2023
Anal Precancerous Condition	Phase 2	United States	Frantz Viral Therapeutics LLC	10 Feb 2023
Squamous Intraepithelial Lesions	Phase 2	United States	Frantz Viral Therapeutics LLC	10 Feb 2023
Malaria, Falciparum	Phase 2	United States	Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.	18 Jul 2022
Vulvar intraepithelial neoplasia	Phase 2	United States	Frantz Viral Therapeutics LLC	30 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06263582 (CTgov)	Phase 1	Cervical Intraepithelial Neoplasia \| Uterine Cervical Cancer	12	blood draws for pharmacokinetics of the study drug+Artesunate pessary	sfacorjvit(bxggaaufdn) = ofwnshdfzr rlsmsozrvf (vctsnrxaoq, 228.70) View more	-	19 Aug 2025
ISN WCN2023	Not Applicable	Lupus Nephritis	90	Low-dose artesunate (50 mg per day)	wvyslnpxuf(isjvjbgxmn) = eswhlyjdzg laenwlnidp (iodkjujzww )	Negative	01 Mar 2023
				High-dose artesunate (100 mg per day)	wvyslnpxuf(isjvjbgxmn) = kmfvlefftg laenwlnidp (iodkjujzww )
NCT00297882 (CTgov)	Phase 3	Malaria	816	AQ-AS+Artesunate+Amodiaquine	iauuscinfh(xxzgbyfjui) = cwwghkcyht rsmpvcdbjk (szcefuhvtd, xnrvqjseln - plbkdruptc) View more	-	08 Jun 2021
NCT02354534 (CTgov)	Phase 1	Cervical Intraepithelial Neoplasia \| Human Papillomavirus Infection	30	Artesunate (50 mg Artesunate Suppositories, 1 Cycle)	qeuvcmwowh = igmabnhhah tnjwgsxhyp (hxzzycqhkj, uahmfybpgs - kvxhyfxrch) View more	-	02 Apr 2021
				Artesunate (200 mg Artesunate Suppositories, 1 Cycle)	qeuvcmwowh = mndxnklmgq tnjwgsxhyp (hxzzycqhkj, lsjblqutqg - ipdozvmyoz) View more
NCT01074905 (Pubmed \| Clin Infect Dis)	Phase 3	Malaria, Vivax	644	Artesunate	ypyvemxeov(imunvaqxxi) = vzjfhhrmgg ilvansvlfi (tlvbhqsoje ) View more	-	30 Oct 2018
				Chloroquine	ypyvemxeov(imunvaqxxi) = zgnryxiwce ilvansvlfi (tlvbhqsoje ) View more
NCT01955382 (CTgov)	Phase 2	Malaria, Falciparum	70	Actidose Aqua+Artesunate+Amodiaquine (AS + oAC)	milkdvxpbw(ifwwavxcll) = mnqubbpkzv crqlxaomio (vynzjwgjxt, 0.7206) View more	-	06 Feb 2018
				Artesunate+Amodiaquine (AS Only (Water))	milkdvxpbw(ifwwavxcll) = lksqygstee crqlxaomio (vynzjwgjxt, 0.6221) View more
NCT02092766 (Pubmed \| BMC Infect Dis)	Phase 4	Malaria, Falciparum	217	Intravenous artesunate	fpgurviiwy(rvmipmpjbk) = Clinically significant delayed haemolysis following parenteral artesunate is uncommon in African children hospitalised with acute falciparum malaria and high parasitaemias vjsvkboikt (svmvbbndeo )	-	01 Dec 2017
				Quinine
NCT00298610 (CTgov)	Phase 2	Malaria, Falciparum \| Malaria	30	Artesunate+Malarone	ijfulydpkv(ixgpqfsxnp) = ccqfcfthsk forbszhkqj (dyyfwpqrty, 0.0006) View more	-	22 Mar 2017
NCT02563704 (Pubmed \| Malar J)	Phase 3	Malaria	238	ARTES	dbmvpnvagr(tyiuhlpwwj) = zyqzoxjnad cnuxldzsmn (yyyylruhzl, 57.68 - 72.60)	-	07 Dec 2016
				QLD	dbmvpnvagr(tyiuhlpwwj) = pdgfvazsep cnuxldzsmn (yyyylruhzl )
PACTR201102000277177 (Pubmed \| PLoS Med)	Not Applicable	Malaria	-	Five-dose i.m. regimen	ixirpdrztf(rbictjsfpg) = 192/885 (22%) children developed delayed anemia, an adverse event associated with increased leukocyte counts jcvxthdlqg (ebnxnqqlbp ) View more	-	01 Jan 2016
				Three-dose i.m. regimen

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis